KN 057
Alternative Names: KN-057Latest Information Update: 31 Dec 2024
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antihaemorrhagics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia
Most Recent Events
- 24 Dec 2024 Suzhou Alphamab plans a phase II trial for Haemophilia A and Haemophilia B (Treatment-experienced) (SC, Injection) in February 2025 (NCT06747416)
- 01 Apr 2024 Alphamab initiates a phase III trial for Haemophilia (In adolescents, In adults, In the elderly) in China (SC) (NCT06569108)
- 09 Jan 2024 Phase-III clinical trials in Haemophilia (In the elderly, In adults, In adolescents) in China (SC) (NCT06312475)